Aurobindo Pharma Reports Q1 Financial Results; Approves Amalgamation and Business Transfer

Aurobindo Pharma Reports Q1 Financial Results; Approves Amalgamation and Business Transfer​

Aurobindo Pharma Limited has released its unaudited financial results for the first quarter ended June 30, 2026. The results include both standalone and consolidated performance figures, alongside updates on major corporate developments including a proposed amalgamation of subsidiaries and a business transfer.

The company reported significant operational activity across various segments during the period, confirmed by the Independent Auditor's Review Report. Management utilized this quarter to pursue strategic moves such as acquiring stakes in solar power companies and completing targeted share buybacks.

Financial Performance Snapshot​

Based on the unaudited standalone results for the quarter ended June 30, 2026 (amounts in ~ million), the company reported Total revenue from operations at 27,995.1. Total income reached 30,414.0, leading to a Profit after tax of 7,372.2.

The standalone financial data is provided below:


For the consolidated results for the quarter ended June 30, 2026, total revenue from operations stood at 91,503.5 million. Total income was reported at 94,145.8 million, with a Profit after tax attributable to Owners of the Parent Company amounting to 10,325.6 million.

Consolidated financial data:

Strategic Corporate Actions and Investments​

The Board of Directors considered and approved several key corporate actions during its meeting on August 5, 2026:

• Amalgamation Proposal: A proposal was put forward to file a Scheme of Amalgamation with the Hon'ble NCLT, Hyderabad. This scheme involves the merger of Eugia Steriles Private Limited and Eugia SEZ Private Limited—wholly owned step-down subsidiaries of the Company—with Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma Limited.
• Buyback: The Board previously approved the buyback of 5,423,728 fully paid-up equity shares for an aggregate value not exceeding 8,000.0 million (excluding transaction costs). The total amount paid for the buyback was 8,065.3 million, including related expenses.
• Business Transfer: A transfer of domestic branded generic pharmaceutical formulations products business was approved via a Business Transfer Agreement to Auropharm Limited, a wholly owned subsidiary of the Company. This transfer occurred on April 1, 2026, and resulted in the net assets of the business being transferred at a consideration of 1,432.1 million.
• Acquisitions and Investments: During the quarter, the company undertook several strategic moves:

* On June 29, 2026, the company completed the acquisition of 100% membership interest in Lannett Company LLC, along with its subsidiaries Silarx Pharmaceuticals Inc, Kremers Urban Pharmaceuticals Inc and Cody Laboratories Inc. The purchase consideration was 23,348.8 million (USD 247.1 million).
* On June 25, 2026, the company invested approximately 5.2 million to acquire a 26% stake in Swarnaakshu Solar Power Private Limited.
* In addition, Apitoria Pharma Private Limited (a wholly owned subsidiary) approved the acquisition of an 80% ownership interest in the A1 Biochem Group for USD 13.6 million.

The group operates in only one reportable segment: Pharmaceuticals, as per Ind AS 108. The unaudited consolidated financial results are backed by the review reports issued by statutory auditors.

AUROPHARMA Stock Price Movement​

Aurobindo Pharma Limited shares climbed today, settling at ₹1613.4 after gaining 1.73% in the session. The robust rally brought the stock close to its annual high, trading on a volume of 1.39 million shares.